MERIT-HF: Benefits of ß-blockade in women with heart failure and reduced left ventricular function
Under-representation of women in heart failure (HF) clinical trials has created uncertainty about the efficacy of various treatment strategies in women. Now, a new analysis by Ghali and coworkers of women in the Metoprolol Controlledrelease Randomized Intervention Trial in Heart Failure (MERIT-HF) provides evidence that women with HF and reduced left ventricular ejection fractions (LVEF) live longer and are hospitalized less frequently if they receive ß-blocker therapy.1
The benefits of ß-blockade in women were similar to those in men.
References are listed at the end of the Data Alert.
Download DA9.ppt (5 slides - 0.7MB)